Intellectual Ventures

Intellectual Ventures, often referred to as IV, is a privately held American invention capital and private equity company headquartered in Bellevue, Washington. Founded in 2000 by Nathan Myhrvold, Edward Jung, Peter Detkin, and Gregory Gorder, the company focuses on intellectual property. Intellectual Ventures reported over $5 billion under management and more than 40,000 intellectual property assets in active monetization programs, and claimed to have generated $2 billion in licensing revenue historically. The company employed approximately 800 individuals worldwide in earlier reports.

Intellectual Ventures' core business model revolves around acquiring and aggregating patents into large portfolios, then licensing these patents to third parties or pursuing legal damages for alleged infringement. While often characterized as a Non-Practicing Entity (NPE) or patent assertion entity (PAE) by critics, Intellectual Ventures states its mission is to energize and streamline the invention economy. The company operates through investment funds such as the Invention Investment Fund (IIF) and the Invention Development Fund (IDF), and has also launched the Intellectual Ventures Lab for research and development, resulting in spinout companies and inventions like malaria detection systems.

Based on the provided data, Intellectual Ventures exhibits a patent assertion posture, appearing as a plaintiff in all 1 of its tracked cases and as a defendant in none. This aligns with its business model of monetizing intellectual property through licensing and litigation rather than producing goods or services. The single tracked case, Intellectual Ventures v. Capital One, was filed on July 3, 2013, in the U.S. District Court for the Eastern District of Virginia.

Intellectual Ventures has historically been a significant player in the patent landscape, noted as one of the top-five owners of U.S. patents as of 2011. The company has attracted both investment from major tech firms like Microsoft and Intel and controversy, with some critics labeling it as a "patent troll." While the company has previously been highly litigious, more recent reports suggest a shift in focus towards investing in research-based efforts and launching spinout companies.